CerbB2 status in breast cancer: Pathologic issues

Annals of the Academy of Medicine Singapore

Volumn 31, Issue 6, 2002, Pages 793-798

  Lian, Siew Chin ^a   Tan, P H ^a  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

Fluorescence in situ hybridisation (FISH); Her2; Herceptest; Herceptin; Immunohistochemistry (IHC)

Indexed keywords

FORMALDEHYDE; ONCOPROTEIN; PARAFFIN;

BREAST CARCINOMA; FLUORESCENCE IN SITU HYBRIDIZATION; GENE IDENTIFICATION; HUMAN; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; LABORATORY TEST; MEDLINE; ONCOGENE NEU; PATIENT SELECTION; REVIEW;

EID: 0036880292     PISSN: 03044602     EISSN: 29724066     Source Type: Journal    
DOI: None     Document Type: Review

References (36)

1. Coussens L, Yang-Feng T L, Liao Y-C, Chen E, Gray A, McGrath J, et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 1985; 230:1132-9.
2. Slamon D J, Clark G M, Wong S G, Levin W J, Ullrich A, McGuire W L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235:177-82.
3. Clark G M. Prognostic and predictive factors. In: Harris J R, Lippman M E, Morrow M, Hellman S, editors. Diseases of the Breast. Philadelphia, PA: Lippincott-Raven, 1996:461-85.
4. Muss H B, Thor A D, Berry D A, Kute T, Liu E T, Koemer F, et al. cerbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 1994; 330:1260-6.
5. Thor A D, Berry D A, Budman D R, Muss H B, Kute T, Henderson I C, et al. erbB-2, p53, and efficacy of adjuvant therapy in lymph nodepositive breast cancer. J Natl Cancer Inst 1998; 90:1346-60.
6. Paik S, Bryant J, Park C, Fisher B, Tan-Chiu E, Hyams D, et al. erB-2 and response to doxorubicin in patients with axillary lymph nodepositive, hormone receptor-negative breast cancer. J Natl Cancer Inst 1998; 90:1361-70.
7. Paik S, Bryant J, Wolmark N. erbB-2 overexpression and response to chemotherapy: NSABP study [abstract 18]. Breast Cancer Res Treat 1998; 50:231.
8. Pegram M D, Lipton A, Hayes D F, Weber B L, Baselga J M, Tripathy D, et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 1998; 16:2659-71.
9. Cobleigh M A, Vogel C L, Tripathy D, Robert N J, Scholl S, Fehrenbacher L, et al. Multinational study of the efficacy and safety of humanized antiHer2 monoclonal antibody in women who have Her2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17:2639-48.
10. Wang S, Saboorian M H, Frenkel E, Hynan L, Gokaslan S T, Ashfaq R. Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridization assays. J Clin Pathol 2000; 53:374-81.
11. Vang R, Cooley L D, Harrison W R, Reese T, Abrams J. Immunohistochemical determination of HER2/neu expression in invasive breast carcinoma. Am J Clin Pathol 2000; 113:669-74.
12. Vincent-Salomon A, Jouve M, Genin P, Freneaux P, Sigal-Zafrani B, Caly M, et al. HER2 status in patients with breast carcinoma is not modified selectively by preoperative chemotherapy and is stable during the metastatic process. Cancer 2002; 94:2169-73.
13. Ellis I O, Dowsett M, Bartlett J, Walker R, Cooke T, Gullick W, et al. Recommendations for HER2 testing in the UK. J Clin Pathol 2000; 53:890-2.
14. Seidal T, Balaton A J, Battifora H. Interpretation and quantification of immunostains. Am J Surg Pathol 2001; 25:1204-7.
15. Baselga J, van de Vijver M J. Testing Her2 status. In: Her2 Monograph. Roche 1999.
16. Bartlett J M S, Going J J, Mallon E A, Watters A D, Reeves J R, Stanton P, et al. Evaluating HER2 amplification and overexpression in breast cancer. J Pathol 2001; 195:422-8.
17. Wick M R, Mills S E. Consensual interpretive guidelines for diagnostic immunohistochemistry. Am J Surg Pathol 2001; 25:1208-10.
18. Jacobs T W, Gown A M, Yaziji H, Barnes M J, Schnitt S J. Her-2/neu protein expression in breast cancer evaluated by immunohistochemistry: a study of interlaboratory agreement. Am J Clin Pathol 2000; 113:251-8.
19. DAKO Atlas for Interpretation of HercepTest™ Staining. DAKO Corporation, 1999.
20. Allred D C, Swanson P E. Testing for erbB-2 by immunohistochemistry in breast cancer. Am J Clin Pathol 2000; 113:171-5.
21. DAKO Hercep-Test™ for Immunoenzymatic Staining. Package insert, March 1999.
22. Roche P C, Ingle J N. Increased Her2 with US Food and Drug Administration-approved antibody [letter]. J Clin Oncol 1999; 17:434.
23. Roche P C, Ingle J N. In reply: The HercepTest Assay: Another Perspective [letter]. J Clin Oncol 1999; 17:2293-4.
24. Schnitt S J, Jacobs T W. Caught between a rock and a hard place. Am J Clin Pathol 2001; 116:806-10.
25. Pauletti G, Godolphin W, Press M F, Slamon D J. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene 1996; 13:63-72.
26. Field A S, Chamberlain N L, Tran D, Morey A L. Suggestions for HER-2/neu testing in breast carcinoma, based on a comparison of immunohistochemistry and fluorescence in situ hybridization. Pathology 2001; 33:278-82.
27. Ravdin P. The use of HER2 testing in the management of breast cancer. Semin Oncol 2000; 27(suppl 9):33-42.
28. st century: Neu opportunities and Neu challenges. Mod Pathol 2001; 14:213-8.
29. Meric F, Hung M C, Hortobagyi G N, Hunt K K. HER2/neu in the management of invasive breast cancer. J Am Coll Surg 2002; 194:488-501.
30. Xing X, Wang S C, Xia W, Zou Y, Shao R, Kwong K Y, et al. The ets protein PEA3 supresses HER-2/neu overexpression and inhibits tumorigenesis. Nat Med 2000; 6:189-95.
31. Yu D, Suen T C, Yan D H, Chang L S, Hung M C. Transcriptional repression of the neu protooncogene by the adenovirus 5 E1A gene products. Proc Natl Acad Sci U S A 1990; 87:4499-503.
32. Hortobagyi G N, Ueno N T, Xia W, Zhang S, Wolf J K, Putnam J B, et al. Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase 1 clinical trial. J Clin Oncol 2001; 19:3422-33.
33. Lebeau A, Deimling D, Kaltz C, Sendelhofert A, Iff A, Luthardt B, et al. HER-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization. J Clin Oncol 2001; 19:354-63.
34. Pauletti G, Dandekar S, Rong H, Ramos L, Peng H, Seshadri R, et al. Assessment of methods of tissue based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization with immunohistochemistry. J Clin Oncol 2000; 18:3651-64.
35. Mass R D, Sanders C, Charlene K, Johnson L, Everett T, Anderson S. The concordance between the clinical trial assay (CTA) and fluorescence in situ hybridization (FISH) in the Herceptin pivotal trials [abstract]. Proc Am Soc Clin Oncol 2000; 19:75A.
36. Ewer M S, Gibbs H R, Swafford J, Benjamin R S. Cardiotoxicity in patients receiving trastuzumab (Herceptin): primary toxicity, synergistic or sequential stress, or surveillance artefact? Semin Oncol 1999;26(suppl 12):96-101.